Last reviewed · How we verify
NCT06732674: RMD-mILDer
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA trial testing A home monitoring strategy with event driven management in Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere in 218 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 218 |
| Start date | 16 December 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 28 February 2028 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- A home monitoring strategy with event driven management
Conditions studied
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere — all drugs for Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere →
- Systemic Sclerosis Pulmonary — all drugs for Systemic Sclerosis Pulmonary →
- Dermatomyositis — all drugs for Dermatomyositis →
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Oslo University Hospital
Who can join
18 and older, any sex, with Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere or Systemic Sclerosis Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology. It is planned as a 2 arm 54 week multi-centre randomised controlled trial to assess outcome of home monitoring with bi-weekly serial forced vital capacity- and patient reported outcome-measurements compared to standard of care with fixed-interval hospital visits in adult patients with rheumatic disease associated interstitial lung diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06732674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06732674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 19 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06732674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing